Dr Sebastian Remberg
Counsel
Sebastian advises private equity funds and other financial sponsors as well as public and private corporates on the full range of M&A and corporate transactions including buyouts, exits, mergers, carve-outs, reorganisations, joint ventures, co-investments as well as consortium and shareholder arrangements.
Sebastian has a particular expertise in the healthcare / life science sector. He spent some time as a secondee at the legal M&A department of a leading global life science Company.
Expertise
Industries
Experience
Representative matters
BC Partners on the acquisition of Tentamus Group GmbH from Auctus.
Partners Group and CVC as a bidding consortium on the intended acquisition of CeramTec Group from BC Partners.
Bridgepoint on the acquisition of a majority stake in the PTV Group, a leading global software company for traffic simulation and planning and a provider of optimization solutions for transport logistics from ultimate owner Porsche SE.
A global pharmaceutical and healthcare company on the sale of its men’s health product Nebido™ (testosterone undecanoate) to Grünenthal.
Published Work
- Sebastian Remberg (2012), "Das Rechtsmissbrauchsverbot als Minderheitenschutz im Gesellschaftsrecht; dargestellt am Beispiel des aktienrechtlichen Squeeze-out", Dissertation
- Sebastian Remberg (2008), "Recht auf Verteidigung und effektiven Rechtsschutz gegen Vermögensbeschlagnahme wegen Terrorismusverdacht durch Ratsbeschluss", European Law Reporter 2008, 60-67
Qualifications
Admissions
Admitted as German Rechtsanwalt, Germany, 2013
Academic
Second German Law Degree, 2013
Dr. iur., University of Freiburg, Germany, 2012
LL.M. University of Queensland, Australia, 2008
First German Law Degree, 2007
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.